Introduction Tumour necrosis factor (TNF)‐α antagonists are effective for the treatment of
plaque‐type psoriasis and psoriatic arthritis, but concerns remain about the safety of these …

Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …

Background Tumor necrosis factor inhibitory agents are currently considered to be
contraindicated in psoriatic patients with hepatitis B. Objective We aim to provide guidance …

Background Issues concerning the potential risks of reactivating chronic hepatitis B virus
arise when the use of anti‐Tumour Necrosis Factor‐α (TNFα) agents is imperative in patients …

Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Background Safety of tumour necrosis factor (TNF) antagonists is a primary concern for
clinicians prescribing them to patients with psoriasis. Objectives To determine the benefit …

Tumor necrosis factor-alpha (TNF-α) inhibitors represent an effective treatment for severe
psoriasis in hepatitis C virus (HCV) patients. The literature reports mainly on short-term …

Background In inflamed skin, keratinocytes and inflammatory cells both produce large
amounts of tumour necrosis factor (TNF)‐α, a cytokine with broad effects that are relevant to …

The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …

Background Adherence is an overall marker of treatment success, and it depends on
multiple factors including efficacy and safety. Despite the wide use of tumour necrosis factor …